Scientists associated with Madras Diabetes Research Foundation (MDRF) find that it often presents with more severe beta-cell dysfunction and relatively less insulin resistance.
The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.
Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, received CDSCO approval this week.
Novo Nordisk scientists have synthesised an insulin molecule that specifically targets glucose in blood, instead of other sugars like fructose, to aid treatment of all types of diabetes.
Doctors Without Borders says new class of drugs & insulin devices could be leading to ‘exorbitant corporate profiteering’. Study published in Journal of the American Medical Association.
Icodec has been touted as a therapy that could eliminate the need for daily or mealtime insulin injections for people with severe diabetes. It has not been approved by any country so far.
Danish pharmaceutical giant Novo Nordisk has said it is set to apply for regulatory approval of its once-a-week insulin drug, Icodec. Results of Phase-3 clinical trial shown 'promising results'.
UK patients may soon be covered for the device, which measures blood glucose, computes amount of insulin needed and then pumps that exact amount into bloodstream.
China and India are home to 1.2 billion young people. They’re the pioneers in advancing the rejuvenation of the Chinese nation and realising the vision of ‘Viksit Bharat 2047’.
The countries signed a memorandum for co-development of UNICORN masts in November 2024. India has been second Asian nation to have such an agreement with Tokyo, after Philippines.
COMMENTS